Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease

Alterations in the production of short-chain fatty acids (SCFAs) may reflect disturbances in the gut microbiota and have been linked to metabolic dysfunction-associated steatotic liver disease (MASLD). We assessed plasma SCFAs in patients with MASLD and healthy controls. Fasting venous blood samples...

Full description

Saved in:
Bibliographic Details
Published in:BMC gastroenterology 2024-01, Vol.24 (1), p.43-10, Article 43
Main Authors: Thing, Mira, Werge, Mikkel Parsberg, Kimer, Nina, Hetland, Liv Eline, Rashu, Elias Badal, Nabilou, Puria, Junker, Anders Ellekaer, Galsgaard, Elisabeth Douglas, Bendtsen, Flemming, Laupsa-Borge, Johnny, McCann, Adrian, Gluud, Lise Lotte
Format: Article
Language:English
Subjects:
Acetic acid
Age
Analysis
Butyrates
Cirrhosis
Complications and side effects
Development and progression
Fatty acids
Fatty Acids, Volatile
Fatty Liver
Fibrosis
Gas chromatography
Health aspects
Humans
Inflammation
Intestinal microflora
Liver cirrhosis
Liver diseases
Logistics
Mass spectroscopy
Metabolic Diseases
Metabolism
Metabolites
Metabolome
Metabolomics
Microbiome
Microbiota
Non-alcoholic fatty liver disease
Non-alcoholic steatohepatitis
Physiological aspects
Plasma
Propionates
Propionic acid
Quality control
Regression analysis
Risk factors
Tandem Mass Spectrometry
Targeted metabolomics
Valerates
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alterations in the production of short-chain fatty acids (SCFAs) may reflect disturbances in the gut microbiota and have been linked to metabolic dysfunction-associated steatotic liver disease (MASLD). We assessed plasma SCFAs in patients with MASLD and healthy controls. Fasting venous blood samples were collected and eight SCFAs were measured using gas chromatography-tandem mass spectrometry (GC-MS/MS). Relative between-group differences in circulating SCFA concentrations were estimated by linear regression, and the relation between SCFA concentrations, MASLD, and fibrosis severity was investigated using logistic regression. The study includes 100 patients with MASLD (51% with mild/no fibrosis and 49% with significant fibrosis) and 50 healthy controls. Compared with healthy controls, MASLD patients had higher plasma concentrations of propionate (21.8%, 95% CI 3.33 to 43.6, p = 0.02), formate (21.9%, 95% CI 6.99 to 38.9, p = 0.003), valerate (35.7%, 95% CI 4.53 to 76.2, p = 0.02), and α-methylbutyrate (16.2%, 95% CI 3.66 to 30.3, p = 0.01) but lower plasma acetate concentrations (- 30.0%, 95% CI - 40.4 to - 17.9, p 
ISSN:1471-230X
1471-230X
DOI:10.1186/s12876-024-03129-7